Health Indicator Report of Prostate Cancer Incidence
Prostate cancer is the most commonly occurring form of cancer (excluding skin cancer) among men and is the second leading cause of cancer death for men in Utah and the U.S. All men over 40 should visit their doctor for a routine health visit which may include a discussion on prostate health.
Prostate Cancer Incidence by Local Health District, Utah, 2012-2014
NotesAge-adjusted to U.S. 2000 population. [[br]] ^ ^^Prior to 2015 San Juan County was part of the Southeast Local Health District. In 2015 the San Juan County Local Health District was formed. Data reported are for all years using the current boundaries.
- The cancer data was provided by the Utah Cancer Registry, which is funded by contract HHSN2612013000171 from the National Cancer Institute's SEER Program with additional support from the Utah Department of Health and the University of Utah
- Population Estimates: National Center for Health Statistics (NCHS) through a collaborative agreement with the U.S. Census Bureau, IBIS Version 2015
DefinitionThe rate of prostate cancer incidence in Utah per 100,000 males.
NumeratorThe number of incidents of prostate cancer among Utah men for a given time period.
DenominatorThe population of Utah for a specific time period.
Healthy People Objective C-19:Increase the proportion of men who have discussed the advantages and disadvantages of the prostate-specific antigen (PSA) test to screen for prostate cancer with their health care provider
U.S. Target: 15.9 percent
How Are We Doing?In 2014, Utah's age-adjusted incidence rate of prostate cancer was 103.3 per 100,000 men. From 2012-2014 Utah Hispanic men had significantly lower incidence rate of prostate cancer (81.6 per 100,000 men) compared to non-Hispanic men (108.8 per 100,000 men). Compared to other racial classifications, from 2012-2014 Black Utah men had the highest prostate cancer incidence with a rate of 194.5 per 100,000 men; this rate was closely followed by Utah Pacific Islander men with a rate of 189.7 per 100,000 men. Meanwhile, Utah Asian and American Indian/Native Alaskan men had significantly lower prostate cancer incidence compared to all races (62.2 and 29.8 per 100,000 men respectively).
How Do We Compare With the U.S.?In 2013 (the most recent U.S. data available), Utah's age-adjusted incidence rate of prostate cancer of 114.3 per 100,000 males was significantly higher than the U.S. rate of 101.6 per 100,000 males.
What Is Being Done?The Utah Department of Health initiated the Utah Cancer Action Network (UCAN), a statewide partnership whose goal is to reduce the burden of cancer. The mission of the UCAN is to lower cancer incidence and mortality in Utah through collaborative efforts directed toward cancer prevention and control. As a result of this planning process, objectives and strategies have been developed by community partners regarding the early detection of cervical, breast, and colorectal cancers as well as the promotion of physical activity, healthy eating habits, melanoma cancer prevention and cancer survivorship advocacy.
Evidence-based PracticesScreening recommendations have changed over time. Until recently, many doctors and professional organizations encouraged yearly prostate-specific antigen (PSA) screening for men beginning at age 50. However, as more has been learned about both the benefits and harms of prostate cancer screening, a number of organizations have begun to caution against routine population screening. Although some organizations continue to recommend PSA screening, there is widespread agreement that any man who is considering getting tested should first be informed in detail about the potential harms and benefits. Currently, Medicare provides coverage for an annual PSA test for all Medicare-eligible men age 50 and older. Many private insurers cover PSA screening as well. Since 2012 the U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer. Healthy diet, exercise, and lifestyle play an important role in cancer prevention.
Page Content Updated On 06/02/2017, Published on 06/07/2017